Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post-immune-oncology and vascular endothelial growth factor receptor targeted therapies Journal Article
| Authors: | Shah, N. J.; Sura, S.; Shinde, R.; Shi, J.; Bupathi, M.; Vickery, D.; Motzer, R. J. |
| Article Title: | Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post-immune-oncology and vascular endothelial growth factor receptor targeted therapies |
| Abstract: | Background: The treatment landscape of metastatic renal cell carcinoma (mRCC) has evolved rapidly with the introduction of various immune-oncology (IO) agents and tyrosine kinase inhibitors (TKIs). We aimed to describe real-world treatment patterns and clinical outcomes of mRCC patients in post-IO and TKI settings. Methods: Using data from The US Oncology Network electronic health record database, iKnowMed, this retrospective cohort study included adult mRCC patients receiving subsequent treatments (index treatment) post-IO and TKI in combination or sequence between 1 January 2018 and 30 September 2020 and followed them until 30 April 2022. Treatment patterns were summarized descriptively. Overall survival (OS) and progression-free survival (PFS) from the index date was described using Kaplan–Meier analysis. Results: We identified 239 patients diagnosed with mRCC who received anticancer treatment post-IO and TKI therapies. The median age was 67 (range: 58, 73) years, 73.6% were male, and 61.5% had an intermediate/poor International Metastatic Renal Cell Carcinoma Database Consortium risk score. Among these, 29 (12.1%) received subsequent therapy at the line of therapy 2 (LOT2), 167 (69.8%) at LOT3, and 43 (18.0%) at LOT4+. The most common subsequent treatments were cabozantinib (38.5%) and axitinib (10.5%). The median OS for LOT2, LOT3, and LOT4+ was 18.0, 17.0, and 26.9 months, respectively. The median PFS for LOT2, LOT3, and LOT4+ was 6.1, 5.0, and 4.0 months, respectively. Conclusions: In mRCC patients treated with IO and TKI in combination/sequence, subsequent LOT choice is diverse, with TKI-based treatments being the most preferred. There is a need for considering treatment sequencing studies and studies with a new mode of action in this population. © 2025 by the authors. |
| Keywords: | overall survival; tyrosine kinase inhibitors; progression-free survival; metastatic renal cell carcinoma; immune-oncology |
| Journal Title: | Cancers |
| Volume: | 17 |
| Issue: | 9 |
| ISSN: | 2072-6694 |
| Publisher: | MDPI |
| Date Published: | 2025-05-01 |
| Start Page: | 1434 |
| Language: | English |
| DOI: | 10.3390/cancers17091434 |
| PROVIDER: | scopus |
| PMCID: | PMC12071004 |
| PUBMED: | 40361361 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work